2 completed, 1 no longer available, 1 terminated. 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow ContraFect: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase Exebacase, Placebo - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 3 | Terminated | ContraFect | 259 | 2019-12-20 | 2023-11-02 |
| Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia CF-301, Placebo - Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Endocarditis | Phase 2 | Completed | ContraFect | 121 | 2017-05-23 | 2021-10-08 |
| A Placebo-Controlled, Dose-Escalating Study to Examine the Safety and Tolerability of Single Intravenous Doses of CF-301 in Healthy Subjects CF-301, Placebo - Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia) | Phase 1 | Completed | ContraFect | 20 | 2015-05-01 | 2020-04-07 |
| Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia Exebacase - MRSA Bloodstream Infection, MRSA Bacteremia | No longer available | ContraFect | 2022-08-31 |
Bacteremia (2) · COVID-19 (1) · Staphylococcal Infections (1)
exebacase (4)
United States (4) · Belgium (1) · Bulgaria (1) · Chile (1) · Czechia (1) · France (1) · Germany (1) · Greece (1) · Guatemala (1) · Israel (1) · Italy (1) · Russia (1) · Spain (1) · United Kingdom (1)